Journal of Hematology and Clinical Research

AcademicKeys
Publons
Google Scholar
Google Scholar

Contact Information

Heighten Science Publications Corporation

+4043820291
jhcr@heighpubs.us
info@heighpubs.us
2504 Stillwater CT, Flower Mound
Texas - 75022, USA

Send us a Mail

We've received your message.
Thank you!
Articles Journals Editors Reviewers
Heighpubs » jhcr » onlineFirst

Online First

  • article icon
    Case Report
    Published: 09/18/2017 | Pages: 1(1): 019-025

    Preservation of Haemostasis with Anti-thrombotic Serotonin Antagonism

    Mark IM Noble* and Angela J Drake-Holland

    An enquiry into the lack of attention awarded to serotonin antagonism in the treatment of arterial thrombosis revealed that the mode of action of serotonin and its platelet receptor antagonists was an action upon thrombus growth, and not, as with other anti-platelet drugs upon the initiation of thrombosis.

    PDF   HTML

  • article icon
    Case Report
    Published: 09/12/2017 | Pages: 1(1): 014-018

    Cytomegalovirus pneumonia and Cryptogenic organizing pneumonia following pediatric stem cell transplantation for leukemia

    Zühre Kaya*, Tuba Şişmanlar, Ayşe Tana Aslan, Öznur Konuş Boyunağa, Işıl Fidan Balcı, İdil Yenicesu and Ülker Koçak

    Background: Knowledge of pulmonary complications (PCs) in children after hematopoetic stem cell transplantation (allo-HSCT) is limited; most data are from adult studies.

    PDF   HTML

  • article icon
    Editorial
    Published: 03/30/2017 | Pages: 1(1): 011-013

    Neutrophil to Lymphocyte Ratio (NLR) in Peripheral Blood: A Novel and Simple Prognostic Predictor of Non-small Cell Lung Cancer (NSCLC)

    Xiaoli Zhang, Ziyuan Zou, Liyu Fan, Xinjie Xu, Yu Siyuan and Peng Luo*

    Lung cancer is the leading cause of cancer-related deaths worldwide, and almost accounts for 20% of these deaths, however, the cure rate is less than 10% [1]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all cases of lung cancer [1], but fewer than 15% of individuals diagnosed with NSCLC can survive for more than 5 years, which poses a great threat to the patient’s life and health [2].

    PDF   HTML

  • article icon
    Review Article
    Published: 01/09/2017 | Pages: 1(1): 001-010

    Primary Cutaneous Lymphomas and Interferon Treatment

    Ajda ERSOY GUNES, Melda COMERT OZKAN*, Fahri SAHIN, Guray SAYDAM

    Primary cutaneous lymphomas (PCLs) are the second most common group of extranodal non-Hodgkin lymphomas (NHL) with an estimated annual incidence of 1/100.000. Interferons (IFNs) are used in mono or combination therapy for cutaneous lymphomas especially for cutaneous T-cell lymphomas (CTCL) for years. IFN-α is the most widely-used type for cutaneous lymphomas. IFN-α has been shown to be a highly active agent in CTCL with response rates ranging from 40% to 80%. In this review, the current information about PCLs and IFNs treatment is summarized.

    PDF   HTML